Salarius Pharmaceuticals, Inc. 8-K

What Happened

• Salarius Pharmaceuticals, Inc. (SLRX) reconvened its 2025 Annual Meeting of Stockholders on December 31, 2025 (originally held December 19, 2025) and filed final voting results on January 2, 2026.
• As of the record date October 24, 2025 there were 1,051,782 shares outstanding; 417,443 shares (39.7%) were present in person or by proxy, constituting a quorum.
• Stockholders re‑elected the two Class I director nominees — Arnold C. Hanish and William K. McVicar — approved, on a non‑binding advisory basis, the compensation of the company’s named executive officers, and ratified Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal 2025.

Key Details

• Shares outstanding (record date): 1,051,782; shares present/represented: 417,443 (39.7%).
• Director election votes:
  • Arnold C. Hanish — For: 143,525; Against: 11,932; Abstentions: 5,761; Broker non‑votes: 256,225.
  • William K. McVicar — For: 143,599; Against: 10,058; Abstentions: 7,561; Broker non‑votes: 256,225.
• Advisory vote on executive compensation — For: 132,240; Against: 22,606; Abstentions: 6,372; Broker non‑votes: 256,225.
• Ratification of Ernst & Young LLP as auditor — For: 401,439; Against: 12,132; Abstentions: 3,872.

Why It Matters

• The re‑election of both Class I directors and ratification of the auditor provide continuity in Salarius’s board and external audit relationship, which affect oversight and financial reporting processes.
• The advisory approval of executive compensation (non‑binding) signals shareholder sentiment toward management pay as disclosed in the proxy.
• A sizable number of broker non‑votes (256,225) shows many shares were present but not voted on certain proposals — a factor investors may note when assessing the level of active shareholder participation.